Brinker Capital Investments’s Vaxcyte PCVX Stock Holding History

Brinker Capital Investments’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,861	Closed	-$355K	–	2167
2025 Q3	$355K	Buy	9,861 +52	+0.5%	+$1.72K	﹤0.01%	1690
2025 Q2	$319K	Sell	9,809 -3,096	-24%	-$101K	﹤0.01%	1678
2025 Q1	$487K	Buy	+12,905	New	+$1.03M	﹤0.01%	1436
2024 Q4	–	Sell	-2,590	Closed	-$296K	–	1887
2024 Q3	$296K	Sell	2,590 -1,991	-43%	-$179K	﹤0.01%	1526
2024 Q2	$346K	Sell	4,581 -267	-6%	-$18.2K	﹤0.01%	1412
2024 Q1	$331K	Sell	4,848 -2,457	-34%	-$170K	﹤0.01%	1420
2023 Q4	$443K	Buy	7,305 +1,050	+17%	+$54.5K	0.01%	1261
2023 Q3	$319K	Buy	+6,255	New	+$309K	﹤0.01%	1351

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brinker Capital Investments's PCVX Position: Q4 2025 in Review

Brinker Capital Investments sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 9,861 shares — an estimated $355K sold.

Brinker Capital Investments first reported a position in PCVX in Q3 2023 and held it in 8 quarters. The position peaked at $487K in Q1 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Brinker Capital Investments reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Brinker Capital Investments sold 9,861 Vaxcyte shares in Q4 2025, an estimated $355K.
Brinker Capital Investments first reported a position in Vaxcyte in Q3 2023 and held it in 8 quarters.
Brinker Capital Investments's Vaxcyte position peaked at $487K in Q1 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Brinker Capital Investments's 13F filing for Q4 2025, filed 12 Feb 2026.